THE GALIEN FOUNDATION

PRODUCT: **EVENITY®**

COMPANY: Amgen

THERAPEUTIC AREA & INDICATION:
Osteoporosis in post-menopausal women at high risk of bone fracture

ABOUT THE PRODUCT

EVENITY (romosozumab-aqqg) is the only osteoporosis therapy that delivers the dual therapeutic effects of increased bone formation and to a lesser extent decreased bone resorption.[1] Approved in the U.S. on April 9, 2019, EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.[1,2] Nearly 12,000 women with postmenopausal osteoporosis were studied in three phase 3 trials. EVENITY rapidly increased bone density and reduced vertebral fracture risk within 12 months.[1,3]

References: 1. EVENITY (romosozumab-aqqg) prescribing information, Amgen.
2. EVENITY (romosozumab-aqqg) FDA approval letter, April 9, 2019.
3. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585-1594.